Dashboard PDUFA PDUFA History Dilution Watch Downside Radar Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Follow the companies behind these drugs with free AI briefings, catalyst countdowns and dilution alerts.

Start 7-day free trial → Log in

Dapolsertib · MEN1703, SEL-24

Small molecule · Inhibitor of PIM-1, PIM-2 and PIM-3

Phase 1/2 Most advanced trial (none active)

1 Registered trials

What is Dapolsertib?

Dapolsertib is an orally available inhibitor of PIM-1, -2, and -3 serine/threonine kinases and mutant FLT3 tyrosine kinase. It interrupts G1/S cell cycle progression and induces apoptosis in tumor cells overexpressing PIMs or expressing mutant FLT3. It is studied in acute myeloid leukemia.

Summary written with AI from the sources listed at the end of this page.

At a glance

Also known as: MEN1703, SEL-24, SEL24-B289
Drug type: Small molecule
Targets: PIM-1, PIM-2, PIM-3, FLT3
Mechanism: Inhibitor of PIM-1, PIM-2 and PIM-3
Pathways: G1/S cell cycle transition, apoptosis
Therapy area: Oncology
In trials of: MEDP
FDA status: Investigational, not approved in the US. Most advanced trial: Phase 1/2
UNII: 9M7X64VTLI

🧪 Clinical trials

Trial	Phase	Condition	Status	Sponsor
NCT03008187	Phase 1/2	Acute Myeloid Leukemia	Completed	MEDP

Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.

Conditions studied

Acute Myeloid Leukemia

Other drugs acting on PIM1 / PIM2 / PIM3 / FLT3

Gilteritinib FDA approved Midostaurin FDA approved Pexidartinib FDA approved BMF-500 Phase 1 CDX-301 Phase 2 CLN-049 Phase 1 Lomonitinib Phase 2/3

Sources

Updated Oct 3, 2026.

Data: FDA (Drugs@FDA, Purple Book, DailyMed), NIH (NCI Thesaurus, GSRS, RxNorm), ClinicalTrials.gov • Informational purposes only, not medical or investment advice. • All drugs A–Z